Bacillus anthracis, the causative agent of anthrax disease, is lethal owing to the actions of two exotoxins: anthrax lethal toxin (LT) and oedema toxin (ET). The key tissue targets responsible for the lethal effects of these toxins are unknown. Here we generated cell-type-specific anthrax toxin receptor capillary morphogenesis protein-2 (CMG2)-null mice and cell-type-specific CMG2-expressing mice and challenged them with the toxins. Our results show that lethality induced by LT and ET occurs through damage to distinct cell types; whereas targeting cardiomyocytes and vascular smooth muscle cells is required for LT-induced mortality, ET-induced lethality occurs mainly through its action in hepatocytes. Notably, and in contradiction to what has been previously postulated, targeting of endothelial cells by either toxin does not seem to contribute significantly to lethality. Our findings demonstrate that B. anthracis has evolved to use LT and ET to induce host lethality by coordinately damaging two distinct vital systems.
Bacillus anthracis, the causative agent of anthrax disease, is lethal owing to the actions of two exotoxins: anthrax lethal toxin (LT) and oedema toxin (ET). The key tissue targets responsible for the lethal effects of these toxins are unknown. Here we generated cell-type-specific anthrax toxin receptor capillary morphogenesis protein-2 (CMG2)-null mice and cell-type-specific CMG2-expressing mice and challenged them with the toxins. Our results show that lethality induced by LT and ET occurs through damage to distinct cell types; whereas targeting cardiomyocytes and vascular smooth muscle cells is required for LT-induced mortality, ET-induced lethality occurs mainly through its action in hepatocytes. Notably, and in contradiction to what has been previously postulated, targeting of endothelial cells by either toxin does not seem to contribute significantly to lethality. Our findings demonstrate that B. anthracis has evolved to use LT and ET to induce host lethality by coordinately damaging two distinct vital systems.
Bacillus anthracis, the causative agent of anthrax, causes disease by growing to high numbers in the blood and secreting the anthrax exotoxins, consisting of three components: protective antigen (PA), lethal factor (LF) and oedema factor (EF) 1 . PA is the receptor-binding moiety that binds to either tumour endothelium marker-8 (TEM8, also called anthrax toxin receptor 1 (ANTXR1)) or CMG2 (also called anthrax toxin receptor 2 (ANTXR2)) on target cells [2] [3] [4] . LF and EF then bind to receptor-associated PA and are transported to the cytosol. The in vivo toxic effects of LT and ET are principally mediated through PA binding to CMG2 (ref. 4) . EF, which with PA forms ET, is a calmodulindependent adenylate cyclase that elevates intracellular cAMP levels and has been shown to cause skin oedema and lethality in experimental animals 5, 6 . LF, which forms LT with PA, is lethal to animals. LF is a Zn
12
-dependent metalloproteinase that cleaves and inactivates the mitogen-activated protein kinase kinases [7] [8] [9] and inflammasome sensor NLRP1 (refs 10, 11) .
The toxins have essential roles in anthrax pathogenesis 12 . At the early stages of infection, LT and ET coordinately impair the immune system to establish infection 13, 14 . At later stages, the toxins accumulate to high levels and cause death through mechanisms that are still not fully understood, despite studies in challenge models ranging from zebrafish to non-human primates [14] [15] [16] [17] [18] . The consequences of targeting specific tissues or cell types cannot be accurately assessed in systemic challenge models. In this study we generated various cell-type-specific CMG2-null mice as well as the corresponding cell-type-specific CMG2-expressing mice, and identified the key tissue targets of LT and ET.
LT targeting of endothelial cells is not lethal to mice
Anthrax toxins induce a vascular shock state in animal models 15 , and this has been proposed to be due to their effects on the endothelium 14, [17] [18] [19] [20] [21] .
To assess the role of endothelial cells, we generated endothelial-cellspecific CMG2-null mice (CMG2 fl/fl /Cdh-cre, hereafter referred to as CMG2(EC) 2/2 ) ( Table 1 and Extended Data Fig. 1a, b ) in which the endothelial-cell-specific deletion of CMG2 was verified. Endothelial cells isolated from the lungs of CMG2(EC) 2/2 mice were 300-fold more resistant than endothelial cells from control CMG2 fl/fl mice to FP59 (refs 22, 23) , an LF fusion toxin that kills cells in a PA-dependent manner (Extended Data Fig. 1c ). CMG2(EC) 2/2 endothelial cells also became resistant to proliferation arrest induced by LT (Extended Data  Fig. 1d ). Interestingly, CMG2(EC) 2/2 endothelial cells were completely resistant to a PA mutant (PA(L687A)) that binds preferentially to CMG2 over TEM8 (Extended Data Fig. 1e, f) , further confirming the complete deletion of CMG2 in CMG2(EC) 2/2 endothelial cells. In contrast, cells other than endothelial cells (non-endothelial cells) from both CMG2(EC) 2/2 and control CMG2 fl/fl mice were similarly sensitive to both PA variants (Extended Data Fig. 1c, f) . Thus, CMG2, the major anthrax toxin receptor in endothelial cells, was specifically and completely deleted from endothelial cells in CMG2(EC) 2/2 mice. To determine the role of targeting endothelial cells in LT pathogenesis in vivo, we challenged the CMG2(EC) 2/2 mice with 100 mg LT. Notably, the CMG2(EC) 2/2 mice displayed similar sensitivity compared with their CMG2(EC) 1/2 and CMG2 1/1 littermates in a manner independent of challenge route, whereas whole-body CMG2 2/2 mice were completely resistant (Fig. 1a and Extended Data Fig. 1g, h ). Therefore, LT targeting of endothelial cells seems not to be required for lethality.
To examine the possibility that damaging endothelial cells alone would induce symptoms or lethality, we also generated CMG2 transgenic mice in which CMG2 was expressed only in endothelial cells. The CMG2 transgenic vector contains a loxP-stop-loxP (LSL) cassette 24 with an enhanced green fluorescent protein (eGFP) coding sequence located between the ubiquitous CAG promoter and the CMG2 transgene (Extended Data Fig. 2a) . Thus, the resulting transgenic mice (LSL-CMG2) exhibited whole-body green fluorescence and did not express the transgene until bred with tissue-specific cre-transgenic mice, allowing loss of the LSL cassette and fluorescence in that particular tissue. Endothelial-cell-specific CMG2-expressing mice (CMG2 EC , Table 1) were obtained by breeding LSL-CMG2 mice with Cdh-cre mice, and by subsequent breeding with whole-body CMG2 2/2 mice to eliminate expression of the endogenous CMG2. We confirmed the endothelialcell-restricted expression of the CMG2 transgene by demonstrating the regained sensitivity of endothelial cells from CMG2 EC mice to PA plus FP59 and PA(L687A) plus FP59 (Extended Data Fig. 2b, c) . As expected, non-endothelial cells from CMG2 EC and whole-body CMG2 2/2 mice, which only expressed the minor receptor TEM8, had similar intermediate sensitivities to PA plus FP59 and were fully resistant to PA(L687A) plus FP59 (Extended Data Fig. 2b, c ). These results demonstrate that the CMG2 transgene is specifically expressed in endothelial cells of CMG2 EC mice. We then challenged the CMG2 EC mice with LT. Notably, all the CMG2 EC mice survived two doses of 100 mg LT, whereas all their littermate CMG2
1/1 and CMG2 1/2 control mice succumbed to the challenges (Fig. 1b) . The above results unequivocally demonstrate that LT targeting of endothelial cells is insufficient to cause lethality in vivo.
LT targets cardiomyocytes and smooth muscle cells
We next examined the effects on LT pathogenesis of targeting the other two major cell types of the cardiovascular system by generating cardiomyocyte-and vascular-smooth-muscle-cell-specific CMG2-null mice ( Table 1 ). The cardiomyocyte-specific CMG2-null mice (CMG2 fl/fl / Myh6-cre; hereafter referred to as CMG2(CM) 2/2 , see Table 1 ) had CMG2 deleted only in heart tissue (Extended Data Fig. 3a, left panel) . The CMG2 fl/fl /SM22-cre mice showed that the deletion occurred both in the aorta (enriched with vascular smooth muscle cells) and the heart (Extended Data Fig. 3a , right panel), and therefore these mice are referred to as CMG2(SM/CM) 2/2 mice (Table 1) , reflecting the fact that they are actually smooth-muscle/cardiomyocyte-specific CMG2-null mice. This is consistent with a previous study showing that the SM22a promoter is active in both smooth muscle cells and cardiomyocytes 25 .
We found that both CMG2(CM) 2/2 and CMG2(SM/CM) 2/2 mice were more resistant than their littermate controls to LT challenge, in that 52% of the CMG2(CM) 2/2 mice and nearly all of the CMG2(SM/CM)
mice survived ( Fig. 2A , B and Extended Data Fig. 3b ). Therefore, cardiomyocytes and smooth muscle cells seem to be major targets for LTinduced lethality.
To verify this finding further, we generated cardiomyocyte-specific (CMG2 CM , Table 1 ) or smooth-muscle-and cardiomyocyte-specific (CMG2 SM/CM , Table 1 ) CMG2-expressing mice using the strategy described for generation of CMG2 EC mice above (Extended Data Fig. 2a and Methods), where loss of GFP expression in cardiomyocytes or cardiomyocytes and smooth muscle cells, but not in other cell types, was verified (Fig. 2C, D and Extended Data Fig. 4) . The activation of the CMG2 transgene occurred selectively in vascular smooth muscle cells in aorta but not in the smooth muscle layer in small intestines and uterus of the CMG2 SM/CM mice ( Fig. 2D and Extended Data Fig. 4b) . Notably, 100% of the CMG2 CM and CMG2 SM/CM mice regained sensitivity and succumbed to two doses of LT (100 mg) whereas all the whole-body CMG2 2/2 and the LSL-CMG2/CMG2 2/2 mice survived without any sign of disease ( Fig. 2E-H) . Sensitivity of the CMG2 SM/CM mice was significantly higher than that of the CMG2 CM mice in that 80% versus 30% of these mice, respectively, were killed by only one dose of LT (P 5 0.05) (Fig. 2E-H) . These results clearly demonstrate that cardiomyocytes as well as smooth muscle cells are key targets of LT.
Although nearly all mice with the CMG2 deletion in smooth muscle cells and cardiomyocytes survived one dose of LT challenge ( Figs 2B  and 3a) , most of the mice were unable to survive two doses (Fig. 3b) . This suggests that other target cells could contribute to lethality at higher doses of toxin. To evaluate whether the additional deletion of CMG2 in endothelial cells could augment the LT resistance of CMG2(SM/CM) Table 1 ) and found that they were more resistant to LT than CMG2(SM/CM) 2/2 mice (Fig. 3a, b ). These results demonstrate that the LT-induced lethality was largely due to targeting the three major cell types of the cardiovascular system through the CMG2 receptor, with LT targeting of endothelial cells contributing to the disease progression only at higher doses.
Serum levels of c-troponin-I, a cardiomyocyte-specific protein that is elevated during cardiac injury, were significantly increased in wild-type and CMG2(EC) 2/2 mice but remained low in both CMG2(CM) 2/2 and CMG2(SM/CM) 2/2 mice 48 h after LT challenge (Fig. 3c) . Consistent with this, echocardiographic analyses showed that heart function was significantly compromised in LT-treated wild-type mice but not
2/2 and CMG2 2/2 mice (Fig. 3d) . Whole-body CMG2-null CMG2
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Histological analyses showed regions of cardiomyocyte degeneration in LT-treated wild-type but not CMG2 2/2 mice (Extended Data Fig. 5 ). Modest hepatocyte degeneration was also found in LT-treated wildtype but not CMG2 2/2 mice, perhaps reflecting previously reported LT-induced hypoxia-mediated liver damage (see below). No obvious abnormalities were found in the lungs, kidneys and spleens of the LTtreated mice (data not shown).
Resistance to B. anthracis infection
B. anthracis normally exists in spore form in the environment and germinates to toxin-producing vegetative bacteria at 37 uC in mammalian hosts. We next infected the CMG2(SM/CM/EC) 2/2 mice with toxigenic, unencapsulated B. anthracis Sterne strain spores. Notably, all the CMG2(SM/CM/EC) 2/2 mice survived the spore challenge whereas littermate heterozygous control mice ( 
CMG2(SM/CM/EC)
2/2 mice were also more resistant than the littermate controls to infection with pre-germinated vegetative B. anthracis (75% versus 18% survival, P , 0.006) (Fig. 3f) . Thus, CMG2 deficiency in the three major cell types of the cardiovascular system is sufficient to confer resistance to LT as well as to anthrax Sterne strain infection.
Liver is not a key target of LT
Early work in our laboratory showed hypoxia-mediated damage in the liver in response to LT 15 . In light of the above results which reveal that LT primarily induces lethality through targeting the cardiovascular system, any effects in the liver are probably secondary events. In support of this hypothesis, we found that hepatocyte-specific CMG2-null mice (CMG2 Fig. 7a ), whereas hepatocyte-specific CMG2-expressing mice (CMG2 Hep , Table 1 ) were completely resistant to the toxin (Extended Data Fig. 7b, c) . These results clearly demonstrate that liver is not a key target of LT.
ET causes intestinal fluid influx and liver oedema
Oedema toxin is another important anthrax toxin relevant to anthrax pathogenesis 1 . Subcutaneous injection of ET induces oedema in experimental animals. To determine whether ET also causes oedema in internal organs and to define its cell-type targets, we first measured the wet/dry ratios of various organs of mice injected with ET. ET SM/CM transgenic mice, but occurred in the hepatocyte-specific CMG2-expressing CMG2 Hep mice at levels equal to and even exceeding those in CMG2 1/1 mice (Fig. 4d) . Thus, ET induces liver oedema by acting directly on hepatocytes rather than endothelial cells and smooth muscle cells. Similarly, ET-induced skin oedema was also due to directly targeting cell types other than endothelial cells and smooth muscle cells (Extended Data Fig. 8a ). We did not detect wet/dry ratio increases in the heart, spleen, kidney and lung of the ET-treated mice (Extended Data Fig. 8b-f) , indicating that the oedema induced by ET was limited to certain tissues including skin and liver and not a general result of cAMP increases in all organs. Indeed, significant decreases in wet/dry ratios of lungs from ET-treated mice were detected (Extended Data Fig. 8f) , probably reflecting the general dehydration status of the ET-treated mice resulting from fluid displacement to skin, liver and other tissues.
Liver is a key target of ET-induced lethality
To define the cell types that are responsible for ET-induced lethality, we next evaluated the sensitivities of the various cell-type-specific CMG2-null mice described above to ET. Surprisingly, mice with SM/CM mice (n 5 3), and aorta (a), heart (c), small intestine (f) from LSL-CMG2 mice (n 5 ) showed similar sensitivity to ET as their littermate controls (Extended Data  Fig. 9 ). In contrast, mice with CMG2 deletion only in hepatocytes (CMG2(Hep) 2/2 ) displayed remarkable resistance to ET, with 82% surviving challenge (Fig. 5a) . Notably, although all the ET-treated CMG2(Hep) 2/2 survivors did show initial signs of malaise, these mice recovered within 3 days of the challenge (Fig. 5a, right panel) . We further tested the sensitivities of the various cell-type-specific CMG2-expressing mice to ET. Mice that expressed CMG2 only in endothelial cells, cardiomyocytes and vascular smooth muscle cells as well as the whole-body CMG2 2/2 mice remained resistant to ET and did not show significant signs of disease (Fig. 5b) . In contrast, the CMG2 Hep mice were fully sensitive to ET (Fig. 5b) . Furthermore, the liver damage biomarkers aspartate aminotransferase and alanine aminotransferase were found to be significantly higher in ET-treated CMG2 1/1 and CMG2 Hep mice than in CMG2 2/2 controls (Fig. 5c ). Histological analyses readily identified necrotic areas in livers of ET-treated wild-type but not CMG2 2/2 mice (Extended Data Fig. 5b ). Only scattered degenerated cardiomyocytes were found in ET-treated wild-type, but not CMG2
2/2
, mice (Extended Data Fig. 5b ). No obvious abnormalities were identified in the lungs, kidneys and spleens of ET-treated mice (data not shown). Together, the above results clearly demonstrate that hepatocytes (but not endothelial cells, cardiomyocytes or smooth muscle cells) are the key cell target of ET-induced lethality.
Discussion
Generation and analysis of the cell-type-specific CMG2-null mice, and the corresponding cell-type-specific CMG2-expressing mice, have allowed us to identify the target cell types responsible for lethality induced by anthrax toxins. Expression of the major toxin receptor CMG2 in cardiomyocytes and smooth muscle cells (but not in hepatocytes) is required for LT-induced lethality, whereas CMG2 expression in hepatocytes (but not in cardiomyocytes and smooth muscle cells) is critical for ET-mediated lethality. Therefore, B. anthracis has evolved to use the two distinct exotoxins to induce lethality by coordinately damaging two vital but distinct systems the cardiovascular system and liver to complete the pathogen's life cycle. Notably, 
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The relative importance of LT and ET in anthrax infections remains uncertain. LF and EF have been measured in the blood of infected animals. In nearly every successful measurement of toxin levels, LF concentrations exceeded those of EF. A recent analysis of in vivo toxin levels in anthrax-infected rabbits found LF at 10-35 mg ml 21 by 48 h and EF at about fivefold lower concentrations 26 . The 5:1 ratio of LF:EF has also been found in other anthrax infection models 27, 28 . Thus, it is likely that lethal doses of ET may only be achieved in the very late stages of anthrax infection and that the majority of symptoms of infected animals may be caused by LT. Consistent with this view, we observed that the LT-resistant mice created in this study are much more likely to survive anthrax infections.
The findings reported here may have value in understanding the pathogenesis of human anthrax infections. Recognition that the anthrax toxins are targeting the cardiovascular system (LT) and liver (ET) may suggest specific supportive therapies that would limit tissue damage and increase survival. Re-examination of the clinical course, pathology and autopsy reports of the relatively few well documented human anthrax cases 29, 30 in light of the data presented here may provide additional insights.
METHODS SUMMARY
In toxin challenge experiments, 8-10-week-old mice with various genotypes were injected with LT or ET either intraperitoneally or intravenously. B. anthracis spores were prepared from the non-encapsulated, toxigenic B. anthracis Sternelike strain A35 (refs 31, 32) . For infection studies, mice were injected with 4 3 10 8 A35 spores subcutaneously or 2 3 10 6 A35 vegetative bacteria via tail vein. For the tissue wet/dry ratio measurements, mice treated with PBS or ET were killed by CO 2 inhalation, and organs collected and weighed. Organs were dried by incubation in an oven at 45 uC overnight. Endothelial cells were isolated and cultured as described previously 33 . For cytotoxicity assays, endothelial cells were grown in 96-well plates and treated with serial dilutions of PA or PA(L687A) combined with 100 ng ml
21
FP59 for 48 h. Cell viabilities were then assayed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) as described previously 34 . Generation of the tissuespecific CMG2-null mice and the corresponding tissue-specific CMG2-expressing mice, anthrax toxin protein purification, endothelial cell isolation, and other methods are detailed in the Methods.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Generation of tissue-specific CMG2-null mice. Mice having the CMG2 transmembrane-domain-encoding exon 12 flanked by loxP sites (a floxed allele), namely, the CMG2 fl/fl mice (C57BL/6 background), were described previously 4 . To generate mice having CMG2 deleted only in endothelial cells, the CMG2 fl/fl mice were mated with Cdh-cre transgenic mice 35 (Cre-recombinase under the VEcadherin promoter) (006137, the Jackson Laboratory). Endothelial-cell-specific CMG2-null mice (CMG2(EC) 2/2 ) were obtained by the subsequent intercrossing of the resulting CMG2 1/fl /Cdh-cre mice (see Table 1 for nomenclature). Similarly, to generate mice with CMG2 deleted in cardiomyocytes, smooth muscle cells, hepatocytes and intestine epithelial cells, the CMG2 fl/fl mice were mated with Myh6-cre (ref. 36) (Cre-recombinase under cardiomyocyte-specific a myosin heavy polypeptide 6 promoter) (011038, the Jackson Laboratory), SM22-cre (ref. 37) (Crerecombinase under the vascular smooth-muscle-specific smooth muscle protein 22a promoter) (017491, the Jackson Laboratory), Alb-cre (ref. 38) (Cre-recombinase under mouse albumin promoter) (003574, the Jackson Laboratory), and Vil-cre (ref. 39) (Cre-recombinase under mouse intestinal-epithelial-cell-specific villin 1 promoter) (004586, the Jackson Laboratory) transgenic mice, respectively. All the tissue-specific Cre mice had been backcrossed to C57BL/6 for at least ten generations when purchased from the Jackson Laboratory, thus the resulting tissuespecific CMG2-null mice used in this study harbour LT-resistant Nlrp1 alleles, and are resistant to LT-induced rapid myeloid cell death. Gene-targeted and transgenic mice used in this study are listed in Table 1 .
Genotyping was performed by PCR using mouse ear DNA. In analysing CMG2 expression, total RNA isolated from various mouse tissues using TRIZOL reagent (Invitrogen) was reverse transcribed using the SuperScript III Reverse Transcriptase (Invitrogen). The 451-bp transmembrane-containing CMG2 cDNA fragment was amplified from wild-type tissues using a forward and reverse primer pair, as listed in Extended Data Table 1 . These primers amplify a 355-bp transmembrane-deleted CMG2 cDNA fragment from CMG2 transmembrane-domain-deleted tissues. Two biological replicates were performed for reverse transcription (RT)-PCR analyses of tissue-specific deletion of CMG2. Generation of tissue-specific CMG2 transgenic mice. Mouse full-length CMG2 cDNA was isolated by RT-PCR from mouse bone-marrow-derived macrophages and cloned into EcoRI/NheI sites of pCLE vector 24, 40 , resulting in CMG2 transgenic vector pCLEmCMG2 containing mouse CMG2 cDNA under the control of the CAG promoter (P CAG , a combination of the cytomegalovirus early enhancer element and chicken b-actin promoter). A loxP-stop-loxP cassette (LSL, a DNA fragment containing eGFP coding sequence followed by a poly(A) terminator 24 ) flanked by loxP sites was placed between P CAG and CMG2 cDNA (Extended Data  Fig. 2a) . After removing the non-relevant part by XhoI and DraIII digestions, the transgenic vector was microinjected into the pronuclei of fertilized eggs to generate transgenic mice (C57BL/6 background). The founder lines were genotyped by Southern blot analyses. Because P CAG is a ubiquitous promoter, the resulting transgenic mice (LSL-CMG2) exhibit whole-body green fluorescence and thus could be identified with GFP visualization using GFP visualization goggles (Model FHS/F-00, BLS). The transgenic mice do not express the CMG2 transgene until bred with cell-type-specific cre-transgenic mice to remove the LSL cassette and place P CAG adjacent to the CMG2 cDNA (Extended Data Fig. 2a) . Thus, endothelial-cell-specific CMG2-expressing mice (CMG2 EC ) were obtained by breeding the green LSL-CMG2 mice with Cdh-cre mice to delete the LSL cassette only in endothelial cells, and by subsequent breeding with whole-body CMG2 2/2 mice to eliminate expression of the endogenous CMG2 gene. Cardiomyocyte-, smooth-muscle/cardiomyocyte-, intestinal-epithelial-and hepatocyte-specific CMG2-expressing mice were generated similarly using the corresponding celltype-specific Cre-expressing mice. The PCR primers for genotyping these mice are listed in Extended Data Table 1 . CMG2 transgenic mice were generated by SAIC/NCI-FCRDC-Frederick under contract with the National Institute of Allergy and Infectious Diseases. Animal studies. All animal studies were carried out in accordance with protocols approved by the National Institute of Allergy and Infectious Diseases Animal Care and Use Committee. In LT challenge experiments, 8-10-week-old male and female mice with various genotypes were injected with one or two doses of 100 mg LT (100 mg PA plus 100 mg LF) in 0.5 ml PBS intraperitoneally or 50 mg LT in 0.2 ml PBS intravenously. In ET challenge experiments, mice described above were injected 25-50 mg ET in 0.2 ml PBS intravenously or in 0.5 ml PBS intraperitoneally. PA, LF, EF and FP59 proteins were purified from a non-virulent B. anthracis strain as previously described [41] [42] [43] . For infection studies, B. anthracis spores were prepared from the non-encapsulated, toxigenic B. anthracis Sternelike strain A35 (ref. 31) as previously described 32 . Mice were injected with 4 3 10 8 A35 spores subcutaneously. For vegetative bacterial infections, mice were injected with 2 3 10 6 A35 bacteria via tail vein. Our previous studies demonstrate that 5-10 mice per treatment group are sufficient for statistical analyses in toxin challenge experiments 4, 13, 15 . Thus, we use 5-10 or more mice per group to ensure statistical power. At least two biological replicates were performed for each toxin challenge experiment. The mice were grouped based on genotypes. When the mice in the same genotype received different treatments, they were randomly assigned to treatment groups. We used the following criteria to score mouse disease progression induced by LT or ET: 0, healthy mouse; 1, slight ruffled coat but no problem in running around cage; 2, ruffled coat and decrease in activity; 3, ruffled coat, hunched posture and little movement; 3.5, moribund; 4, found dead. All toxin-challenged or infected mice were monitored twice daily for 2 weeks after challenge for signs of malaise or mortality by investigators and animal caretakers who were unaware of genotypes.
For the tissue wet/dry ratio measurements, mice treated with PBS or ET were killed by CO 2 inhalation, and organs collected and weighed. Organs were dried by incubation in an oven at 45 uC overnight. For the footpad skin oedema model, mice were injected intradermally in one foot pad with 0.25 mg ET in 20 ml PBS. Footpad oedema was monitored at 8 and 20 h after injection by measuring dorsal/ planar and medial/lateral sizes using digital calipers.
Murine c-troponin-I ELISA kit (Life Diagnostics) was used to measure the cardiac biomarker c-troponin-I in mouse serum samples according to the manufacturer's protocol. Mice of various genotypes were treated intraperitoneally with 100 mg LT and bled at indicated time points after challenge for serum c-troponin-I measurements. For echocardiography studies, mice were kept under isoflurane anaesthesia on a heating pad with body temperature monitoring (by anal probe) throughout the procedure. Baseline left ventricular short and long axis views were obtained with the Vevo 770 system at the NIH Mouse Imaging Facility. All measurements were performed in blinded fashion. Mouse endothelial cell isolation and cytotoxicity assay. Endothelial cells were isolated and cultured as described previously 33 . Briefly, three mouse lungs were digested with type I collagenase and plated on gelatin-and collagen-coated flasks. The cells were then subjected to sequential negative sorting by magnetic beads coated with a sheep anti-rat antibody using a Fc blocker (rat anti-mouse CD16/ CD32, catalogue number 553142, BD Pharmingen) to remove macrophages and positive sorting by magnetic beads using an anti-intermolecular adhesion molecule 2 (ICAM2 or CD102) antibody (catalogue 553326, rat anti-mouse CD102, BD Pharmingen) to isolate endothelial cells (ICAM2 positive cells). The cells other than endothelial cells (non-endothelial cells, ICAM2 negative cells) were also isolated simultaneously as controls. These primary cells were used within 5 passages after isolation. For cytotoxicity assays, endothelial cells, non-endothelial cells, and Chinese hamster ovary (CHO) cells were grown in 96-well plates and treated with serial dilutions of PA or PA(L687A) combined with 100 ng ml
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FP59 for 48 h. PA(L687A) was first described in ref. 44 and found in this study to be a CMG2-preferable PA mutant. FP59 is a fusion protein of LF amino acids 1-254 and the catalytic domain of Pseudomonas aeruginosa exotoxin A that kills cells by ADP-ribosylation of eukaryotic elongation factor-2 after delivery to cytosol by PA 22, 23 . Cell viabilities were then assayed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) as described previously 34 , expressed as percentage of MTT signals of untreated cells. The CHO cells that express only TEM8 (PR230(TEM8)) or CMG2 (PR230(CMG2)) were described previously 42 . Histology. Mice treated with PBS, LT (100 mg, intraperitoneally), or ET (50 mg, intravenously) were killed by CO 2 inhalation, and hearts, livers, lungs, kidneys and spleens collected and fixed in 4% paraformaldehyde for 24 h, embedded in paraffin, sectioned, stained with haematoxylin/eosin and subjected to microscopic analysis. Statistical analyses. GraphPad Prism 6 was used for statistical analyses. For comparison of mouse survival curves, the log-rank (Mantel-Cox) test was used. For differences in tissue oedema between two groups, the two-tailed unpaired Student's t-test was used. P , 0.05 was considered statistically significant. ARTICLE RESEARCH
